Enigma Diagnostics Showcases the Enigma ML as a Service Provider at InnovHealth Summit 2010 in Abu Dhabi

OXFORD, England and SAN DIEGO, April 22, 2010 - Enigma Diagnostics Limited, the decentralised and point-of-care molecular
diagnostics company, announced today that it will be a product provider at
the InnovHealth - Middle East Healthcare Innovations Summit in Abu Dhabi on
25 and 26 April 2010 and will be presenting the Enigma ("Mini Laboratory")
instrument system.

The Enigma ML is a fully automated, multi-sample, multi-plexing
diagnostic instrument with integrated sample preparation and will deliver
results from swab samples in less than 60 minutes, allowing clinical
professionals to 'test and treat' in a single appointment. This simple to use
system which requires minimal operator training, combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) to provide
laboratory standard results.

InnovHealth 2010, organised by business information company naseba and
endorsed by the UAE Ministry of Health, recognises Enigma as a pioneer in
providing innovative healthcare solutions to the regions' progressing
healthcare industry. Facilitating strategic networking, the event hosts the
region's high-profile healthcare leaders, all of whom will benefit from
informative conference sessions and panel discussions during the two-day
summit.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation
rapid molecular diagnostic instrument platforms for decentralized and
point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) with the simplicity
needed for decentralized and point-of-care testing providing results from a
raw sample in less than 60 minutes. The Company is targeting a number of
multi-billion pound markets, core among which are the Clinical and high-value
Applied Markets. Enigma's commercialisation strategy is to maximize revenues
from a continuous flow of market leading rapid diagnostic point-of-care
instrument and assay platforms, based on unique technologies and underpinned
by its broad Intellectual Property portfolio. Enigma will partner with market
leaders where global penetration of markets is required and where
appropriate, will engage regional partners and build in-house sales and
marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology
Laboratory to a portfolio of patents, which represent over 15 years of UK
Ministry of Defence funded Research. It also has licences from Applied
Biosystems and Celera Diagnostics for commercialisation of real-time PCR
instruments, and from Roche Molecular Systems to practise HybProbe real-time
PCR chemistry for human and veterinary in vitro diagnostics. Enigma's
in-house RandD activities have generated a portfolio of worldwide patent
families dedicated to real-time PCR and wider molecular technologies. Many of
these patents are granted across a range of core commercial territories
including US, EU and Japan with more extensive filing and grants across a
number of other key territories.

For more information visit www.enigmadiagnostics.com

    UK Contact:

    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44-1980-590131

Enigma Diagnostics: Deborah Cordingley, deborah.cordingley at enigmadiagnostics.com, +44-1980-590131